DGAP-News: PAION AG / Key word(s): Miscellaneous PAION RECEIVES MILESTONE OF GBP 300,000 AFTER CAMBRIDGE COGNITION HOLDINGS LISTS ON LONDON STOCK EXCHANGE 07.05.2013 / 14:00 --------------------------------------------------------------------- PAION RECEIVES MILESTONE OF GBP 300,000 AFTER CAMBRIDGE COGNITION HOLDINGS LISTS ON LONDON STOCK EXCHANGE - Cambridge Cognition, a spin-out of CeNeS, now PAION UK, begins trading on London's Alternative Investment Market Aachen (Germany), 07 May 2013 - PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, General Standard: PA8), a biopharmaceutical company, announced today that Cambridge Cognition Holdings PLC (AIM: COG), a spin-out of CeNeS, now PAION UK, began trading on the Alternative Investment Market (AIM) of the London Stock Exchange, on 18 April 2013. Cambridge Cognition specialises in computerised neuropsychological tests including those enabling the early detection of dementia. The spin-out of Cambridge Cognition from CeNeS, now PAION UK, was announced in May 2002. The total value of the agreement was £1 million payable to CeNeS. Of this total consideration, GBP 700,000 was paid in upfront and stage payments and an additional GBP 300,000 is now payable to PAION due to the AIM listing. 'We will immediately reinvest the money in the further development of Remimazolam', said PAION CEO Dr Wolfgang Söhngen. 'We wish Cambridge Cognition all the best in their future as a public company.' ### About PAION PAION AG is a publicly-listed biotech company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION AG is transforming its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products to take advantage of the unique profile of its main compound, Remimazolam. Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. End of Corporate News --------------------------------------------------------------------- 07.05.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulierter Markt in Frankfurt (General Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 209980 07.05.2013
DGAP-News: PAION RECEIVES MILESTONE OF GBP 300,000 AFTER CAMBRIDGE COGNITION HOLDINGS LISTS ON LONDON STOCK EXCHANGE
| Source: EQS Group AG